4D Molecular Therapeutics, Inc. (FDMT) Financials

FDMT Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 492.6 million 85.0 million
March 31, 2026 512.9 million 61.1 million
Dec. 31, 2025 566.7 million 61.0 million
Sept. 30, 2025 424.0 million 55.0 million

FDMT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -70.1 million 5.9 million
March 31, 2026 -68.1 million 4.5 million
Dec. 31, 2025 27.9 million 5.6 million
Sept. 30, 2025 -46.4 million 4.5 million

FDMT Net Income

No data available :(

FDMT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 361.3 million 14.3 million 14.3 million
March 31, 2026 390.9 million - 20.5 million
Dec. 31, 2025 402.7 million - 21.4 million
Sept. 30, 2025 305.1 million - 22.3 million

FDMT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 70.3 million
March 31, 2026 68.1 million
Dec. 31, 2025 57.9 million
Sept. 30, 2025 56.1 million

FDMT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 55000 68.3 million 12.5 million -
March 31, 2026 - 65.0 million 11.7 million -
Dec. 31, 2025 631000 57.6 million 12.8 million -
Sept. 30, 2025 91000 49.4 million 11.8 million -

FDMT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 3.8 million 2.1 million
March 31, 2026 3.0 million 2.1 million
Dec. 31, 2025 85.1 million 2.0 million
Sept. 30, 2025 90000 47.2 million

FDMT Revenue by Segment
Graph available only for paid members. Upgrade to see it.

FDMT

Price: $12.14

52 week price:
6.96
16.93

Earnings Per Share: -2.63 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 192795

Market Capitalization: 667.8 million

Links: